Concerns About Stopping GLP-1 Medications

Boxes of Ozempic and Wegovy by Novo Nordisk are now prevalent, with about 1 in 8 adults in the U.S. using them.

However, ceasing these medications might have serious consequences.

A recent study from Washington University School of Medicine, published in BMJ Medicine, suggests that even brief interruptions in GLP-1 treatment can significantly increase the risk of heart attacks, strokes, and mortality for individuals with Type 2 diabetes. The researchers analyzed electronic health records of over 333,000 diabetes patients, most of whom were prescribed Novo Nordisk’s Ozempic.

Key findings include:

• Continuous use of GLP-1 medications over three years reduced cardiovascular risks by 18%.
• Stopping these medications for just six months led to a 4% increase in risk compared to ongoing use.
• A two-year break in treatment raised that risk to 22% compared with those who continued their medications.

Study author Dr. Ziyad Al-Aly emphasized in an interview that GLP-1s do more than just promote weight loss. They also alleviate back issues, reduce cholesterol and blood pressure, enhance insulin sensitivity, reduce inflammation, and offer heart protection.

Dr. Al-Aly described the phenomenon of stopping GLP-1s as “metabolic whiplash,” where all the positive effects quickly reverse after treatment ends.

This isn’t shocking, as GLP-1 medications are recognized for their heart health benefits. In 2024, the FDA approved semaglutide, the active ingredient in Wegovy and Ozempic, for reducing major heart event risks in adults with existing heart conditions and obesity.

Nonetheless, this recent research provides significant evidence about the impacts of discontinuing these drugs, particularly for those managing diabetes. It sheds light on the ongoing issue of high discontinuation rates, attributed to difficulties in accessing the drugs and side effects like nausea. As reported, discontinuation rates can vary between 36% to 81% in several studies.

Dr. Al-Aly urges both healthcare providers and patients to recognize that remaining on these treatments is crucial for long-term health benefits. He noted the importance of addressing the main reasons for stopping the medications, particularly by proactively managing side effects. The situation may improve in the U.S. as major companies like Eli Lilly work on expanding insurance coverage for obesity medications and as Medicare plans to start covering weight loss treatments.

It’s important to remember that maintaining treatment shouldn’t be an afterthought. There’s a significant cost associated with stopping the medication.

Pharmaceutical companies are also investigating ways to reduce discontinuation rates, aiming to create next-gen obesity and diabetes treatments that offer similar benefits but with fewer side effects.